EUVIMEDSkopri EUVIMED
EditorialKommentar

Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV ‐infected individuals treated with pegylated interferon—Implications for stopping rules and the HBV cure programme. Authors' reply

Chan Xie iD

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.18174 ↗

At a glance

Editorial in Alimentary Pharmacology & Therapeutics, 2024. Written by Chan Xie. Institution: Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Major MEDLINE topics: Antiviral Agents. 8 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

LINKED CONTENT This article is linked to Chen et al papers. To view these articles, visit https://doi.org/10.1111/apt.18131 and https://doi.org/10.1111/apt.18142

Subjects

MeSH terms (MEDLINE)

Antiviral AgentsHumansB7-H1 AntigenPolyethylene GlycolsProgrammed Cell Death 1 ReceptorInterferon-alphaHepatitis B, ChronicHepatitis B virusHepatitis B

Substances

Antiviral AgentsB7-H1 AntigenPolyethylene GlycolsProgrammed Cell Death 1 ReceptorInterferon-alphaCD274 protein, human

Authors and institutions

  • Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.

ORCID profiles: Chan Xie

Cite

APA

Xie, C. (2024). Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV ‐infected individuals treated with pegylated interferon—Implications for stopping rules and the HBV cure programme. Authors' reply. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18174

Vancouver

Xie C. Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV ‐infected individuals treated with pegylated interferon—Implications for stopping rules and the HBV cure programme. Authors' reply. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18174

BibTeX
@article{Xie2024,
  author = {Xie, Chan},
  title = {Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV ‐infected individuals treated with pegylated interferon—Implications for stopping rules and the HBV cure programme. Authors' reply},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.18174}
}
Start for free →